KYNTRA BIO, INC. 8-K

What Happened
Kyntra Bio, Inc. announced in an 8-K filed June 9, 2026 that on June 2, 2026 it received $4.0 million from AstraZeneca Treasury Limited. This payment is the second and final holdback under the February 20, 2025 share purchase agreement and completes the collection of amounts owed to Kyntra related to the August 29, 2025 sale of its China operations.

Key Details

• Sale closed August 29, 2025: total consideration of approximately $220 million (about $85M enterprise value + ~$135M net cash in China).
• Cash paid at closing: $210 million; post-closing amounts: $10.0 million subject to holdbacks.
• Holdbacks: $6.0M for final net cash adjustments (received Nov 2025 plus an additional $0.4M adjustment) and $4.0M for indemnity claims (received June 2, 2026).
• No indemnity claims were made; receipt of the $4.0M completes all payments under the Share Purchase Agreement.

Why It Matters
This filing confirms Kyntra has collected all remaining cash from its divestiture of China operations, improving its cash position by the final $4.0M and removing contingent indemnity exposure related to that transaction. For investors, it provides closure on a prior acquisition/divestiture event and confirms no outstanding holdbacks or indemnity claims remain tied to the sale.